ARTES Biotechnology - Contract Research for Recombinant Protein Production

ARTES Biotechnology is a profitable German contract research company, providing innovative solutions in recombinant protein production to pharmaceutical companies (Red Biotechnology) and to feed / food / fine chemical enzyme manufacturers (White Biotechnology).

GENE EXPRESSION SERVICES - YEAST EXPRESSION

The focus of our service and license offer is on gene expression in the high-yield methylotrophic yeast expression system Hansenula polymorpha. The platform technology of ARTES Biotechnology is secured by our own IP and exclusive licenses.

ARTES Biotechnology's experienced staff and an international network of strategic partners provide customised service packages. These cover the areas of gene analysis and design, production strain generation and characterisation, fermentation development and downstream processing, as well as process upscale and cGMP production.

ARTES Biotechnology's high standards in contract research and project documentation form the basis for fast product commercialisation, best demonstrated by successful FDA approvals and European clinical studies of clients´ proteins, ranging from enzymes to therapeutic products.

FEASIBILITY STUDIES FOR RECOMBINANT STRAINS

ARTES Biotechnology offers tailor-made feasibility studies for the generation of recombinant Hansenula strains to provide the most efficient solution for your protein production. We can offer a team with more than 15 years' experience in contract research and in gene expression trouble-shooting to focus on your individual project.

Our proven track record in yeast expression research and the broad platform of tools and technologies available from ARTES Biotechnology have already developed a number of registered and marketed products. The ideal combination of efficient gene expression elements and secretion signals, specially engineered host strains and short, inexpensive fermentation strategies allow for high-yield, economically feasible protein production. Deliverables include characterised production strains and a professional documentation suitable for further registration purposes.

A number of products derived from Hansenula are already marketed worldwide (e.g. hepatitis B vaccine, Insulin, Interferon alpha2a, Hirudin, feed / food enzymes such as oxidases and lipases). Several other products are in clinical trials, such as elafin. These products and clients such as Danisco A/S, DSM, Fuji Photo Film, IOGEN, Novozymes A/S, Proteo Biotech AG are the perfect proof for the reliability of the technology offered by ARTES Biotechnology.

SYSTEM SCREENING SERVICE

In our system screening service, we evaluate for the client a variety of microbial expression systems (yeast, fungi and bacteria) for the expression of a specific heterologous protein. Within four months, we provide a first comparison of expression levels and preliminary protein characteristics. After selecting the best system, the next phase will include a dedicated production strain generation and optimisation.

FERMENTATION DEVELOPMENT, UPSCALE PROCESS AND cGMP CONTRACT MANUFACTURING

Following the successful supply of production strains, ARTES Biotechnology can act as your general contractor for all further steps of product development. Via a network of academic and industrial partners, ARTES Biotechnology can ensure fermentation development, upscale processing service and cGMP manufacturing at scales up to 1,000L.

GLOBAL TECHNOLOGY LICENSING – SERVICE AND LICENSE FROM ONE SOURCE

ARTES Biotechnology offers internationally protected systems, technologies and products, as well as unpatented know-how and expertise. All relevant license rights required for commercialisation of your product can be obtained from only one source. Terms and conditions are flexibly adapted to your business case and linked tightly to commercial success.

HIRUDINIZED BLOOD TEST TUBE

One of the Hansenula derived products, recombinant Hirudin, has been successfully developed for the coating of blood withdrawal tubes. ARTES Biotechnology offers this unique approach for complete blood diagnostics from one single collection tube.

The hirudinised blood test tube replaces a number of the currently used devices and opens possibilities for new and improved assays, e.g. in molecular genetic diagnostics. This mass product demonstrates the competetiveness of the Hansenula technology and the efficiency of ARTES Biotechnology's global licensing strategy.